Home / Business and Economy / Judge Denies Block on Weight-Loss Drug Ads
Judge Denies Block on Weight-Loss Drug Ads
27 Oct
Summary
- A judge rejected Novo Nordisk's plea to stop Eli Lilly's drug ads.
- Novo Nordisk claimed Eli Lilly's ads for Zepbound were false.
- The weight-loss drug market is projected to exceed $100 billion.
A United States district judge has refused to block advertisements for weight-loss drugs promoted by Eli Lilly, as requested by rival Novo Nordisk. The Danish drugmaker sought a preliminary injunction, asserting that the advertising for Eli Lilly's Zepbound and Mounjaro was false and misleading.
US District Judge Zahid Quraishi in Trenton, New Jersey, determined that Novo Nordisk did not adequately demonstrate irreparable harm to justify halting the ads. This legal dispute highlights the immense commercial importance of weight-loss medications for major pharmaceutical companies.
Novo Nordisk had filed a lawsuit in July, contending that Eli Lilly's ads improperly compared higher doses of their drugs to lower doses of Novo Nordisk's Ozempic and Wegovy. The company argued these comparisons violated false advertising laws, warranting an injunction.
Eli Lilly has denied any wrongdoing. Novo Nordisk is actively working to solidify its market position in the United States for its injectable obesity drugs. The market for these treatments is anticipated to grow substantially, reaching over $100 billion by the close of this decade.
